Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Asia Pacific Australia

Aussie Health Authorities Flag Tamiflu Flu Drug Shortage in Queensland

This article was originally published in PharmAsia News

Executive Summary

Health authorities of a major Australian state say its influenza cases are outpacing supplies of Roche's Tamiflu (oseltamivir) antiviral drug.

Health authorities of a major Australian state say its influenza cases are outpacing supplies of Roche's Tamiflu (oseltamivir) antiviral drug. They said drug wholesalers are placing urgent orders for more of the drug as the number of cases reached more than 11,000, double that of any other Australian state. The Pharmacy guild of Australia said high demand has just about emptied Queensland stocks of the drug, but Aussie suppliers were attempting to step up their imports of Tamiflu. (Click here for more)

"Flu Spike Sparks Urgent Drug Demand" - ABC News (Australia) (8/24/2012)

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Asia Pacific Australia
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

SC081983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By